Dr. Rath Health Foundation

Dr. Rath Health Foundation

Responsibility for a healthy world Dr. Rath Research Institute 100+ Studies Published In PubMed

The Pharmaceutical "Business with Disease"

Up to date news and comment about the "Business with Disease".

Judge orders cancer treatment for young boy

December 22, 2012

A British High Court judge has ordered radiotherapy to begin on a sick seven-year-old boy whose treatment his New Zealand mother has been trying to stop. Sally Roberts, 37, formerly of Auckland, claimed radiotherapy would cause significant side-effects to her son Neon, and had resisted National Health Service Trust (NHS) attempts to treat him. At one point she took the boy into hiding and then after police found them she has fought to avoid court ordered treatment.
Read article at stuff.co.nz (New Zealand)

Comment: Just like Dominic Feld and his mother before them, Sally Roberts and her son are fighting a brave battle against the Pharma Cartel’s outmoded and inhuman approaches to the treatment of cancer. Rather than allowing children to be treated safely and naturally using the Cellular Medicine approach to cancer, the strategic goal of the Pharma Cartel is to dictatorially ban non-patentable natural treatments and all information about them. To help terminate the cancer epidemic for this generation and for all future generations, please support our international initiative for a ‘Cancer Free World’.

British government announces Thalidomide deal

December 20, 2012

The British government has announced a major new €98m funding agreement for victims of the drug Thalidomide in England, to run over ten years.
Read article at rte.ie (Ireland)

Comment: Despite the devastating effect Thalidomide had on its victims, it is notable that the British Government has still never apologised for the role its drug regulations played in contributing to the scandal.

Taking aspirin for 10 years could double the risk of sight loss

December 18, 2012

Taking aspirin for 10 years could more than double the risk of sight loss, according to a new study.
Read article in the Daily Mail (UK)

Merck Must Provide Vioxx Documents Given To Feds

December 17, 2012

The Vioxx saga is not over yet. And a new court ruling may shed further light on the controversy over the Merck painkiller, which was withdrawn in 2004 over links to heart attacks and strokes. Last week, a federal court judge ruled the drugmaker must provide potentially damaging documents to shareholders who filed a long-running securities fraud lawsuit.
Read article at pharmalot.com

Servier Founder Faces Charges In Mediator Scandal

December 12, 2012

In a rare move not seen in the pharmaceutical industry, Jacques Servier, who founded Servier Laboratories, was formally placed under investigation on suspicion of manslaughter in connection with his role in the scandal over the Mediator diabetes drug, which has been blamed for at least 500 deaths in France, Reuters reports.
Read article at pharmalot.com

Comment: Despite warnings dating back as early as 1998, successive French health ministers ignored scientific advice that Mediator was at best useless, and at worst highly dangerous. Notably, therefore, former French President Nicolas Sarkozy – who, in 2004, coerced the marriage between French pharmaceutical dwarf Sanofi and Swiss/German drug giant Aventis/Hoechst – previously worked for Servier as a lawyer. Now suspected to have killed up to 2,000 people, serious questions as to how Mediator was officially approved, and subsidized for 33 years by the French health service, remain unanswered.

Tamoxifen: Praised As "Life Saving" But Still Causing Cancer

December 12, 2012

Many of the drugs used to treat breast cancer today are probable or known cancer-causing agents. Tamoxifen, for instance, is classified by the World Health Organization as a "human carcinogen," but recent news headlines praised extended use of this drug for "saving lives." It is obvious that the mainstream media has swallowed the tamoxifen-flavored Kool-Aid ... will you?
Read article at greenmedinfo.com

Boehringer Sued by Hundreds Over Bleeding Tied to Pradaxa

December 11, 2012

Hundreds of patients and their families are questioning whether Boehringer executives knew Pradaxa posed a deadly risk to some patients when they brought the drug to the U.S. market in October 2010.
Read article at bloomberg.com

Runaway mother's lawyer pleads with judge for sympathy after she fled with son, 7, fearing cancer treatment would fry his brain

December 7, 2012

The lawyer for a mother who took her critically ill seven-year-old son into hiding today asked the judge for sympathy - because she truly believed cancer treatment would fry his brain.
Read article in the Daily Mail (UK)

Comment: Just like the mother of Dominic Feld before her, by opposing orthodox cancer treatments for her young son, Sally Roberts is fighting an antiquated medical system. Rather than allowing children to be treated safely and effectively using non-patentable natural therapies that can block all key mechanisms that make cancer a deadly disease, the strategic goal of the Pharma Cartel is to ban such treatments and all information about them. To help terminate the cancer epidemic for this generation and for all future generations, please support our international initiative for a ‘Cancer Free World’.

East Germany's secret police sold citizens to western pharmaceutical companies to use as human guinea pigs in drug trials

December 4, 2012

Former Communist East Germany secretly sold its citizens to western pharmaceutical companies to use as human guinea pigs in drug trials.
Read article in the Daily Mail (UK)

Statin Drugs Linked To Worsening Osteoarthritis Of The Knee

November 29, 2012

New research flies in the face of a new theory that statin drugs, used to lower cholesterol, may be of value in those suffering from osteoarthritis. To the contrary, statin drugs are likely contributing to the epidemic of knee osteoarthritis in exposed populations.
Read article at greenmedinfo.com

Roche still resists releasing full data on Tamiflu to independent reviewers

November 27, 2012

The tale of the drug Tamiflu (oseltamivir) just gets curiouser and curiouser.
Read article at minnpost.com (USA)

Researchers identify physiological evidence of 'chemo brain'

November 27, 2012

Chemotherapy can induce changes in the brain that may affect concentration and memory, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Read article at medicalxpress.com

Common Drug Increases Deaths in Atrial Fibrillation Patients

November 27, 2012

Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers.
Read article at sciencedaily.com

Novartis To UK: Speed Drug Approvals, Or Else

November 26, 2012

Frustrated by the process in the UK for approving and adopting the use of new medicines, Novartis has arranged a sort of showdown with a group of government officials, scientists and trustees from the National Health Service in which the drugmaker intends to offer a blunt statement – improve the process or investment, and jobs, will leave the country.
Read article at pharmalot.com

Risk of hemorrhage from warfarin higher in clinical practice than clinical trials show

November 26, 2012

Rates of hemorrhage for older patients on warfarin therapy are much higher than rates reported in clinical trials, found a study published in CMAJ (Canadian Medical Association Journal).
Read article at medicalxpress.com

Pinkwashing Hell: Breast Removal as a Form of "Prevention"

November 26, 2012

Following closely on the heels of the year's most intensive annual cause-marketing campaign, October's Breast Cancer Awareness Month, two chilling events of grave concern to women and their health were widely (but mostly superficially) reported on in the mainstream media.
Read article at greenmedinfo.com

As drug industry’s influence over research grows, so does the potential for bias

November 25, 2012

For drugmaker GlaxoSmithKline, the 17-page article in the New England Journal of Medicine represented a coup. The 2006 report described a trial that compared three diabetes drugs and concluded that Avandia, the company’s new drug, performed best. “We now have clear evidence from a large international study that the initial use of [Avandia] is more effective than standard therapies,” a senior vice president of GlaxoSmithKline, Lawson Macartney, said in a news release. What only careful readers of the article would have gleaned is the extent of the financial connections between the drugmaker and the research.
Read article in the Washington Post (USA)

30 Years of Breast Screening: 1.3 Million Wrongly Treated

November 22, 2012

The breast cancer industry's holy grail (that mammography is the primary weapon in the war against breast cancer) has been disproved. In fact, mammography appears to have CREATED 1.3 million cases of breast cancer in the U.S. population that were not there.
Read article at greenmedinfo.com

How Drug Company Money is Undermining Science

November 21, 2012

The pharmaceutical industry funnels money to prominent scientists who are doing research that affects its products—and nobody can stop it.
Read article on the Scientific American website (USA)

Advair boomed amid health risks

November 17, 2012

The 2001 product launch of the asthma drug Advair was a lavish, Las Vegas affair. Using images of a slot machine, top GlaxoSmithKline executives took the stage in front of thousands of assembled sales reps. "There are people in this room who are going to make an ungodly sum of money selling Advair," one executive told the group. He was right.
Read article on the Milwaukee Journal-Sentinel website (Wisconsin, USA)

Cholesterol Lowing Statins Found To Damage Peripheral Nerves

November 15, 2012

The neurotoxicity of statin drugs are back in the news. Following on the heels of the FDA decision earlier this year to require statin drugs manufacturers to add "memory loss" as a side effect of this chemical class, a new study in published in the Journal of Diabetes reveals a clear association between statin use and peripheral neuropathy in a US population 40 years of age and older.
Read article at greenmedinfo.com

Babies given Calpol and other forms of paracetamol are more likely to develop asthma

November 12, 2012

Babies given Calpol and other forms of paracetamol are more likely to develop asthma before going to school, say Danish researchers.
Read article in the Daily Mail (UK)

Hundreds of Croatian doctors linked to corruption probe

November 12, 2012

Hundreds of doctors in Croatia have been implicated in a corruption probe targeting a local pharmaceutical firm whose management and other workers were detained Monday, a minister said.
Read AFP news report at yahoo.com

US lawsuit extends thalidomide's reach
Drug blamed for a broader range of harmful effects.

November 8, 2012

In a new twist of a historic tragedy, 13 Americans who say they are survivors of thalidomide are suing four companies for producing and distributing the notorious drug. They say that the drug — used by pregnant women for morning sickness until it was discovered to cause severe birth defects — affected more people in the United States than thought, and caused a wider range of deformities. And, they say, the companies have done all they can to hide these facts.
Read article at nature.com

A Rising Anti-Stroke Drug Is Tied to Risk of Bleeding Deaths

November 2, 2012

Dr. Bryan A. Cotton, a trauma surgeon in Houston, had not heard much about the new anticlotting drug Pradaxa other than the commercials he had seen during Sunday football games. Then people using Pradaxa started showing up in his emergency room. One man in his 70s fell at home and arrived at the hospital alert and talking. But he rapidly declined. “We pretty much threw the whole kitchen sink at him,” recalled Dr. Cotton, who works at Memorial Hermann-Texas Medical Center. “But he still bled to death on the table.”
Read article in the New York Times (USA)

Drugmaker Merck agrees to settle Missouri class-action Vioxx lawsuit for up to $220M

November 2, 2012

ST. LOUIS — Merck & Co. Inc. has agreed to settle a class action lawsuit filed on behalf of Missouri consumers over its prescription pain reliever Vioxx in a deal that could cost the drugmaker up to $220 million, lawyers for the consumers said. The agreement announced Thursday would settle claims that New Jersey-based Merck violated the Missouri Merchandising Practices Act by promoting and selling Vioxx, which Merck pulled from the shelves eight years ago because of evidence that it doubled users’ chances of suffering a heart attack or stroke.
Read article in the Washington Post (USA)

Have India’s poor become human guinea pigs?

November 1, 2012

Drug companies are facing mounting pressure to investigate reports that new medicines are being tested on some of the poorest people in India without their knowledge.
Read article on the BBC News website (UK)

Statins side effects warning when combined with other drugs: regulator

October 31, 2012

Hundreds of thousands of people taking a common statin are to have their dose reduced due to fears over side effects, it has emerged.
Read article in the Daily Telegraph (UK)

Drugs giant Roche accused of sitting on trial data for flu treatment
Doubts remain about efficacy and safety of Tamiflu, stockpiled for use in pandemics

October 31, 2012

The pharmaceutical giant Roche is being accused of irresponsibly withholding key trial data about a vital flu drug on which governments around the world have spent billions of pounds.
Read article in The Independent (UK)

Comment: Studies with Tamiflu have reported side-effects including nausea, vomiting, headaches, diarrhea, abdominal pain and even dangerous psychiatric side effects. Notably, therefore, the official World Health Organization guidance on Tamiflu, issued in 2004, which urged governments to stockpile the drug, was authored by scientists who had previously received payment from its manufacturer, Roche.

Die Early with Sleeping Pills

October 29, 2012

A new study shows prescription sleeping pills bring an increased risk of dying early—or getting cancer.
Read article on the Alliance for Natural Health (USA) website

Prozac pregnancy alert: Mothers-to-be on anti-depressants are putting babies at risk, warn scientists

October 26, 2012

Thousands of women who take anti-depressants during pregnancy are endangering their unborn babies, researchers have warned. The widely prescribed pills have been found drastically to raise the odds of miscarriages, premature birth, autism and life-threatening high blood pressure, they say.
Read article in the Daily Mail (UK)

Many Terminal Cancer Patients Put False Hope in Chemo, Study Finds

October 24, 2012

Many people with incurable cancer mistakenly believe chemotherapy may save them, a new study finds. Researchers at Dana-Farber Cancer Institute in Boston found that more than 80 percent of people with advanced colon cancer and nearly 70 percent with advanced lung cancer thought chemo could cure their disease.
Read article on the US News and World Report website

Comment: For decades now, despite their known toxicity and inability to cure cancer, chemotherapy substances have been deceptively promoted as lifesaving “treatments” to millions of cancer patients worldwide. So much so, in fact, that, as this study shows, even patients diagnosed as terminal continue to mistakenly put their faith in them. In reality, the fact is that for many types of cancer it is already established that chemotherapy does not significantly prolong the life of cancer patients at all.

Drug firms are 'risking lives by hiding bad trials and side effects of their medicines'

October 24, 2012

Drug companies are deliberately withholding the results of adverse clinical trials - putting patients at risk, an MP warned yesterday.
Read article in the Daily Mail (UK)

Roche may face fines over drug-safety reporting

October 23, 2012

Europe's drug regulator has started an infringement procedure against Switzerland's Roche to investigate its alleged failure to properly report tens of thousands of potential drug side effects. If found guilty, the world's biggest maker of cancer medicines could be fined up to 5 percent of annual EU turnover which totaled 12.8 billion francs ($13.8 billion) in 2011, or 640 million francs. It was first time the London-based European Medicines Agency (EMA) has launched such proceedings since legislation came into force five years ago.
Read news report at reuters.com

Comment: Considering Roche stands accused of having failed to fully assess up to 80,000 cases of possible adverse drug reactions, with some 15,000 deaths said to be among the reports examined, a $690 million fine for a company that had global revenues of over $47 billion in 2010 would arguably be a drop in the ocean.

Popular antidepressants may raise stroke risk

October 18, 2012

Commonly prescribed antidepressants called selective serotonin reuptake inhibitors (SSRIs) may raise a pill-taker's risk of suffering a stroke.
Read article on the CBS News website (USA)

Comment: In a finding that has been significantly underplayed by the global media, the researchers found that people taking SSRIs were 50 percent more likely to have an intracranial hemorrhage than those not taking antidepressants and a 40 percent elevated risk for having an intracerebral hemorrhage.

Pfizer Settles First Case Over Chantix And Suicide

October 18, 2012

Just as the first trial was to begin over accusations that its Chantix pill for quitting smoking caused a suicide, Pfizer has agreed to a settlement, according to a spokesman for the drugmaker, who declined to disclose the terms. The case was being closely watched because it was considered a bellwether – a potential indicator for how the overall litigation may proceed.
Read article at pharmalot.com

Pfizer Tries To Keep CEO From Chantix Trial

October 12, 2012

In the latest instance in which a drugmaker is trying to keep its ceo from being questioned in front of a jury, Pfizer is appealing an order by a federal judge who recently granted a request that Ian Read and two other execs at the drugmaker take the witness stand in a lawsuit over the safety controversy surrounding the Chantix pill for quitting smoking.
Read article at pharmalot.com

J&J Loses A Preemption Case Over Infant Tylenol

October 10, 2012

In a setback to Johnson & Johnson, the US Supreme Court yesterday declined to review a case in which a family successfully argued that the healthcare giant should have included sufficient warnings about the risks of Infant Tylenol.
Read article at pharmalot.com

Industry too afraid to include children in clinical trials, says expert

October 10, 2012

The pharma industry does not include children in clinical research for fear of mentally scarring them, according to ResearchNurses.co. Responding to a US Food and Drug Administration (FDA) committee’s recent call for more paediatric trials , the home visit services provider told us children could experience lasting “harm” from the distress of research.
Read article at outsourcing-pharma.com

Comment: This admission illustrates one of the many key differences between synthetic patented drugs and natural therapies. Whilst drugs can have serious and even deadly side effects, cause lasting harm and scar patients for life, natural therapies using vitamins are so safe that, according to data collected by the United States National Poison Data System, there was not even a single death caused by a vitamin supplement in the US in 2010.

Pfizer to pay $164 million in investor lawsuit over Celebrex

October 9, 2012

Pfizer Inc has agreed to pay $164 million to settle a shareholder class action accusing the drug maker of misrepresenting the clinical trial results for Celebrex. The settlement was disclosed in court papers filed Friday in U.S. District Court in New Jersey. The accord came about two weeks before the company was to go to trial over allegations that it misled investors by distorting the results of a study of the arthritis drug.
Read news report at reuters.com

The Cancer Lobby

October 6, 2012

Who knew that carcinogens had their own lobby in Washington? Don’t believe me? Just consider formaldehyde, which is found in everything from nail polish to kitchen countertops, fabric softeners to carpets. Largely because of its use in building materials, we breathe formaldehyde fumes when we’re inside our homes. Just one other fact you should know: According to government scientists, it causes cancer. The chemical industry is working frantically to suppress that scientific consensus — because it fears “public confusion.” Big Chem apparently worries that you might be confused if you learned that formaldehyde caused cancer of the nose and throat, and perhaps leukemia as well.
Read article in the New York Times (USA)

Beta-Blocker Use Not Associated With Lower Risk of Cardiovascular Events

October 2, 2012

Among patients with either coronary artery disease (CAD) risk factors only, known prior heart attack, or known CAD without heart attack, the use of beta-blockers was not associated with a lower risk of a composite of cardiovascular events that included cardiovascular death, nonfatal heart attack or nonfatal stroke, according to a study in the October 3 issue of JAMA.
Read article at sciencedaily.com

Oral steroids bring on vitamin D deficiency

October 2, 2012

People on oral steroids are twice as likely to suffer from severe vitamin D deficiency than the general populace, says new research.
Read article at paktribune.com (Pakistan)

The Dark Side of Breast Cancer (Un)Awareness Month

October 1, 2012

Sadly, Breast Cancer Awareness Month is a time of increasing awareness not of the preventable causes of breast cancer, but of the breast cancer industry's insatiable need to both raise money for research into a pharmaceutical cure, and to promote its primary means of "prevention": early detection via x-ray mammography.
Read article at greenmedinfo.com

Seniors dementia risk raised with sleeping pill use

September 27, 2012

People over the age of 65 who take certain sleeping pills or anti-anxiety medications may face a higher risk of developing dementia within 15 years compared with those who never took the pills, a study suggests.
Read article on the CBC News website (Canada)

Confirmed Again: Statin Drugs Calcify The Coronary Arteries

September 27, 2012

A new study published in the journal Atherosclerosis found that statin use is associated with a 52% increased prevalence and extent of coronary artery plaques possessing calcium. This study, published on August 24th, was preceded only three weeks earlier by one in the journal Diabetes Care, which found that coronary artery calcification "was significantly higher in more frequent statin users than in less frequent users," among patients with type 2 diabetes and advanced atherosclerosis.
Read article at greenmedinfo.com

German medics challenge new EU clinical drug trials

September 25, 2012

German doctors have voiced concern about EU plans to speed up clinical drug trials and streamline testing procedures across the 27-nation bloc.
Read article on the BBC News website

Comment: To all intents and purposes, the Brussels EU Commission essentially wants to abandon requirements for full and proper ethical evaluations to be carried out prior to clinical drug trials. Amongst other things, its legislative proposals would undermine clinical trial safeguards for minors and for people incapable of giving consent. In this respect, the historical parallels to these insidious plans are the criminal medical experiments carried out by Nazi doctors working for the IG Farben pharmaceutical and chemical cartel during WWII. Then and now, the key concern of the pharmaceutical business with disease is not the protection of patients – but the profits of its shareholders.

In India, gift-giving drives drug makers' marketing

September 23, 2012

Sales representatives for Abbott Laboratories Inc's Indian subsidiaries know what it takes get a doctor to prescribe the drugs they market: a coffee maker, perhaps, or some cookware, or maybe a vacuum cleaner. These are among the many gifts for doctors listed in an Abbott sales-strategy guide for the second quarter of 2011, a copy of which was reviewed by Reuters. As laid out explicitly in the guide, doctors who pledge to prescribe Abbott's branded drugs, or who've already prescribed certain amounts, can expect some of these items in return.
Read news report at reuters.com

Drug giants fined $11bn for criminal wrongdoing
Fines are not enough to reform drug industry, warn lawyers

September 20, 2012

The global pharmaceutical industry has racked up fines of more than $11bn in the past three years for criminal wrongdoing, including withholding safety data and promoting drugs for use beyond their licensed conditions. In all, 26 companies, including eight of the 10 top players in the global industry, have been found to be acting dishonestly.
Read article in The Independent (UK)

Painkillers 'are the cause' of millions of headaches

September 19, 2012

Up to a million people in the UK have "completely preventable" severe headaches caused by taking too many painkillers, doctors have said. They said some were trapped in a "vicious cycle" of taking pain relief, which then caused even more headaches.
Read article on the BBC News website (UK)

Comment: One of the particular features of the pharmaceutical ‘Business with Disease’ is that maintaining and expanding diseases is a precondition for its growth. A key strategy to accomplish this goal is the development of drugs that merely mask symptoms while avoiding the curing or elimination of diseases. Painkillers for headaches are a classic example of this.

Drug giants give up on Alzheimer's cure
Research too difficult and costly, say pharmaceutical companies

September 19, 2012

The world's leading pharmaceutical companies are downgrading the search for new treatments for Alzheimer's disease after the failure of a series of high-profile drugs trials. The human and financial costs of the disease are growing rapidly as the population ages, but the prospects of treatments to halt it, or slow its progress, are receding as at least five trials in the past five years have delivered disappointing results.
Read article in The Independent (UK)

Comment: The placing of profit before health is one of the main principles governing the pharmaceutical “business with disease.” In this respect, given that September is designated as “World Alzheimer’s Month”, it is notable that the Alzheimer's Association in the United States – a key promoter of the “World Alzheimer’s Month” campaign – has a particularly large number of major multinational pharmaceutical partners and sponsors. As such, it would appear that some of these companies may essentially be advocating the raising of money for drug research into a disease – Alzheimer’s – that they have already given up on. Significantly therefore, natural non-patentable approaches to treating Alzheimer’s disease already exist. To learn about them, click here.

Statins are unlikely to prevent blood clots, analysis finds

September 18, 2012

Despite previous studies suggesting the contrary, statins (cholesterol-lowering drugs) may not prevent blood clots (venous thrombo-embolism) in adults, according to a large analysis by international researchers published in this week's PLOS Medicine.
Read article at medicalxpress.com

J&J CEO Should Be Forced to Testify, Teen’s Lawyers Say

September 18, 2012

Johnson & Johnson’s top executive should be forced to testify about claims that the company illegally marketed the antipsychotic drug Risperdal, which allegedly caused boys to grow breasts, lawyers for a teenager suing the drugmaker said in a court filing.
Read article at bloomberg.com

Common painkillers linked with hearing loss in women

September 13, 2012

Household painkillers are now linked with hearing loss in women – especially those under 50. A recent study by researchers at Brigham and Women’s Hospital in Boston has shown a link between women who take ibuprofen or acetaminophen more than two days a week and an increased risk of hearing loss.
Read article at foxnews.com

Antidepressants, sleeping pills and anxiety drugs may increase driving risk

September 12, 2012

Drugs prescribed to treat anxiety, depression and insomnia may increase patients' risk of being involved in motor vehicle accidents, according to a recent study, published in the British Journal of Clinical Pharmacology. Based on the findings, the researchers suggested doctors should consider advising patients not to drive while taking these drugs.
Read article at medicalxpress.com

How Doctors Do Harm

September 11, 2012

The tide is turning. When once it was unheard of for a doctor's opinion to be challenged, today's patients are getting second and third opinions, seeking out alternative care and pursuing natural, organic solutions to their health issues. And now the medical system is being challenged by none other than the Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society. How We Do Harm: A Doctor Breaks Ranks About Being Sick In America by Dr. Otis Webb Brawley, exposes the nasty side of medicine – those things we hear of, suspect, and experience that erode our confidence in conventional medical treatment.
Read article at greenmedinfo.com

Common painkillers 'increase' risk of early death in heart attack survivors

September 11, 2012

Common painkillers such as ibuprofen increase the risk of dying or having a second heart attack among heart attack survivors, researchers have warned. A study shows that taking the common painkillers can put those who have already had one heart attack at a heightened risk of having another for at least five years. The findings confirm the potential dangers of taking a group of non-steroidal anti-inflammatory drugs known as NSAIDs.
Read article in the Daily Mail (UK)

Jury decides hormone therapy caused Utah woman’s breast cancer

September 7, 2012

A federal jury awarded $5.1 million in compensatory damages to a Utah woman Friday after finding hormone therapy drugs caused her breast cancer and drugmakers were negligent because they failed to adequately warn of that risk on labels provided to doctors and patients. The U.S. District Court jury, comprised of seven women and five men, sat through four weeks of expert testimony and scientific presentations before being handed the case early Wednesday afternoon. They came back with a decision two days later.
Read article on the Salt Lake Tribune website (Utah, USA)

Gruenenthal's thalidomide apology 'insulting'

September 1, 2012

The company which invented thalidomide has "insulted" those affected by the drug by issuing an "insincere" apology, campaigners have said. The drug, sold in the 1950s as a cure for morning sickness, was linked to birth defects and withdrawn in 1961. German-based Gruenenthal has issued its first apology in 50 years, but said the drug's possible side-effects "could not be detected" before it was marketed. But the UK's Thalidomide Trust said any apology should also admit wrongdoing.
Read article on the BBC News website (UK)

Comment: Secret files recently obtained by the Sydney Morning Herald newspaper in Australia reveal that Gruenenthal ignored and covered-up repeated warnings that thalidomide could damage unborn babies. To access legal documents containing these files, click here and here.

Pfizer Loses Bid to Dismiss Fen-Phen Lung Ailment Suits

August 30, 2012

Pfizer Inc. (PFE), whose Wyeth unit reserved more than $21 billion to settle lawsuits over the fen- phen diet drugs, lost its bid to have claims that the pills caused a fatal disease years after users stopped taking them thrown out. U.S. District Judge Harvey Bartle III in Philadelphia today rejected Pfizer’s arguments that there was no reliable evidence that fen-phen could cause an often-fatal lung disease to arise years after a user stopped taking the pills.
Read article at businessweek.com

Blind To The Truth: The Eye-Damaging Effects of Statins

August 28, 2012

Newly published research has raised concern about the possibility that statin drugs are damaging the eyes of those taking them.  Titled, and published in the journal Optometry and Vision Science, researchers found that those taking statin drugs had 48% higher risk of pathological eye lense changes (nuclear sclerosis and cortical cataract) associated with increased opacity, i.e. cataracts.
Read article at greenmedinfo.com

The Latest Lie From The Cancer Industry: 'Don't Worry About Chemotherapy During Pregnancy, It's Perfectly Safe'

August 26, 2012

According to researchers echoing the sentiments of conventional medical wisdom, there is no need to worry about chemotherapy drugs endangering your unborn child if you develop cancer while pregnant, it's perfectly safe. The sales people at Cancer Inc partnering with Big Pharma, Big Medicine and everybody else who generates a profit from the cancer industry, are at it again with their latest sales pitch, this time for pregnant women.
Read article at sott.net

Comment: To enforce its “Business with Cancer”, the Drug Cartel has to ensure that nobody, not even a pregnant woman, is able to escape its dictatorial grasp. Notably, therefore, the extreme toxicity of chemotherapy is reflected in the ‘safety precautions’ for cancer patients published by the so-called ‘American Cancer Society’. Unbeknown to many people, the chemicals used in chemotherapy are toxic and dangerous to others even after they are excreted through the skin, urine, stool, tears, semen or vaginal fluids. The people at particular risk include family members, caregivers and literally anyone touching a chemotherapy patient. Even health professionals are being reminded about the health risks they are exposed to while handling chemotherapy drugs. These risks include damage to their DNA, birth defects, the development of new cancers and organ damage. Thus, health professionals have to wear special gloves, goggles, and gowns when preparing and giving chemotherapy. In view of all this, for the Cartel and its stakeholders to pretend that chemotherapy is somehow “safe” during pregnancy, and that there are no long-term risks to the unborn child, is clearly absurd.

What Conflicts? Cochrane Reviews & Disclosure Info

August 23, 2012

File this under 'basic irony'. The Cochrane Collaboration is generally regarded as a highly reliable and reputable source for evaluating medical evidence. But what happens when researchers hold a mirror up to Cochrane? A new study finds an interesting wrinkle: most Cochrane reviews of drug trials published in 2010 did not provide information on the sources of funding for trials or financial ties and employment held by authors of the trials.
Read article at pharmalot.com

Comment: As we ourselves revealed back in 2008, the Cochrane Collaboration and its study authors have a long history of conflicts of interest and connections to organizations having a strong institutional bias towards orthodox (i.e. pharmaceutical) medicine. To discover what the world’s media didn’t tell you about the notorious 2008 Cochrane “vitamin review”, including its potential historical parallel with crimes committed by the managers of the notorious I.G. Farben Cartel, click here.

211 people died in six months during clinical trials in India

August 18, 2012

NEW DELHI: As many as 211 people died between January and June 2012 due to serious adverse events (SAE) during clinical trials. Investigations are now on to ascertain how many of the deaths were caused by drugs administered to the trial subjects.
Read article on The Times of India website

Is Mandatory Pediatric Chemo Institutionalized Child Abuse?

August 16, 2012

Mandatory chemotherapy for your child. The concept is horrific. But it is not just a concept. It has already happened and is still happening, which is why I am writing this article. We need to sound the alarm about this disturbing trend that, despite recent mainstream media references to a case of court-coerced chemotherapy, is still largely going unnoticed and/or unrecognized for what it really is: a human rights violation of the worst kind. Moreover, as it involves our children who can not rightly advocate for themselves, we need to speak up and act on their behalf.
Read article at greenmedinfo.com

Comment: As the parents of young Dominik Feld learned between 2002 and 2004, the stakeholders of the pharmaceutical 'Business with Disease' will go to almost any lengths in order to prevent its destruction by the forces of Cellular Medicine. Tragically, the battle between the old approach of mainstream medicine, characterised by chemotherapy, and the new medicine heralded by Cellular Medicine's breakthrough, accompanied Dominik to his last moments. To help end the 'Age of Fear' and eventually eliminate cancer as one of the most dreaded diseases of our time, please support our Call for a Cancer Free World.

Statin Drugs Found To Accelerate Arterial Calcification

August 11, 2012

Newly published research reveals that more frequent statin drug use is associated with accelerated coronary artery and aortic artery calcification, both of which greatly contribute to cardiovascular and all-cause mortality. Published Aug. 8th, 2012 in the journal Diabetes Care, researchers studied patients with type 2 diabetes and advanced atherosclerosis and found that coronary artery calcification "was significantly higher in more frequent statin users than in less frequent users." Furthermore, in a subgroup of participants initially not receiving statins, "progression of both CAC [coronary artery calcification] and AAC [aortic artery calcification] was significantly increased in frequent statin users."
Read article at greenmedinfo.com

Drugs companies putting profit ahead of medical discoveries, warn scientists

August 8, 2012

The multi-billion pound pharmaceutical industry has spent the last decade developing new drugs which have produced little benefit and caused considerable harm, experts say today.
Read article in The Independent (UK)

Comment: With each passing day, the facts about the pharma industry and its "Business with Disease" are becoming known to more and more people. In this respect it is interesting to recall that, not so many years ago, Dr. Rath's analysis- that it is not in the pharma industry's financial interests to prevent common diseases, and that the maintenance and expansion of diseases is a precondition for its financial growth - may initially have seemed controversial to some. Today, however, with this reality becoming increasingly accepted by millions of people all over the world, the stage is gradually being set for the establishing of a new global healthcare system. Unlike the fraudulent "Business with Disease" and its deep-rooted ideology of Profit Over Life, this new system of healthcare will be based upon scientific breakthroughs in the areas of vitamin research and cellular health and the understanding that a chronic deficiency of micronutrients is the most frequent cause of today's most common diseases. Moreover, it will operate not in the interests of profit - but in those of the people.

Pfizer To Pay $60M For Making Foreign Bribes

August 7, 2012

As promised, the US Securities and Exchange Commission has charged Pfizer with violating the Foreign Corrupt Practices Act after finding various subsidiaries bribed doctors and other health care professionals employed by foreign governments in order to win business.
Read article at pharmalot.com

Chemo 'could aid cancer growth'

August 7, 2012

Chemotherapy can backfire by helping healthy body cells to fuel treatment-resistant cancer and growth, research has shown. The surprise discovery suggests that many forms of cancer treatment can actually make the disease tougher to tackle. Almost all solid tumour cancers, such as those affecting the breast, prostate, lung and bowel, ultimately stop responding to chemotherapy.
Read news report at msn.com

Comment: Far from this being a "surprise discovery", the truth is that it has long been known that many of the drugs used in chemotherapy cause new cancers. In fact, amongst these substances are some of the most toxic chemicals known to man. The first chemotherapy drug was derived from 'mustard gas', a chemical warfare agent used in World War I as a weapon. Significantly, therefore, drug derivatives of this deadly gas are still being used in cancer patients today as mechlorethamine, cyclophosphamide, chlorambucil and ifosfamide. To learn about a real research breakthrough that promises to turn cancer from being an almost certain 'death verdict' into a manageable disease, click here.

Disavow A Paxil Study Once And For All?

August 7, 2012

A decade ago, the Journal of the American Academy of Child and Adolescent Psychiatry published a paper concluding that the Paxil antidepressant, which is sold by GlaxoSmithKline, was "generally well tolerated and effective for major depression in adolescents" (here it is). But the study has since been discredited amid charges that primary and secondary outcomes were conflated, selective results were reported and ghostwriting was involved. Nonetheless, the paper has never been retracted and the universities whose academics were listed as co-authors failed to rebuke the authors.
Read article at pharmalot.com

Bayer's Yasmin Lawsuit Settlements Rise to $402.6 Million

July 31, 2012

Bayer AG said settlements of U.S. lawsuits over claims that its Yasmin line of birth-control pills caused blood clots in women have increased to more than $402 million.
Read article at bloomberg.com

Comment: Long-term intake of estrogen and other hormones - both as hormonal contraception and hormone replacement therapy during menopause - causes a depletion of vitamins and other cellular nutrients in the body. This is the reason why women taking these hormones have an increased risk for heart attacks, strokes and other forms of cardiovascular disease. Notably therefore, several previous studies have already shown that women taking hormonal contraceptives ("the Pill") significantly increase their risk for cardiovascular disease.

German drug maker covered up warnings about thalidomide risk

July 26, 2012

Secret files reveal the German maker of thalidomide ignored and covered-up repeated warnings that its drug could damage unborn babies. The Herald has obtained excerpts of never-before-published files from pharmaceutical giant Grunenthal's archives, which detail the explicit warnings the company received about its drug's potential to harm foetuses well before it was withdrawn from sale in late 1961. An estimated 10,000 babies worldwide were born in the late 1950s and '60s with severe physical deformities because their mothers had taken thalidomide drugs, which were marketed as a safe sedative and remedy for morning sickness.
Read article in the Sydney Morning Herald (Australia)

Comment: To access legal documents containing the confidential Grunenthal files, click here and here.

New fridges defend against drug-laced drinking water

July 25, 2012

The eco- and health-conscious among us have warned for a while now that all those expired pain-killers, birth control pills and antibiotics some people flush down the toilet are coming back to haunt us in the form of pharmaceutical-laced drinking water. Up until now, those who wanted to avoid such contamination could buy a filter for their kitchen taps that would, hopefully, draw out most of the drug residues. But GE has now unveiled a line of refrigerators with built-in filtration systems specifically aimed at reducing concentrations of pharmaceuticals in water and ice. According to GE, tests show the new French door fridges remove 98 percent of five trace pharmaceuticals: ibuprofen, atenolol, fluoxetine, progesterone and trimethoprim.
Read article at greenbang.com

Comment: Whilst this development is arguably a promising step in the right direction, the fact remains that the actual numbers of pharmaceuticals known to be present in water supplies around the world are staggering. In the United States, for example, a vast array of drugs have been found. In one particularly notable set of test results, officials in Philadelphia discovered 56 pharmaceuticals or byproducts in treated drinking water. For the time being, therefore, until such time as the 'Business with Disease' is brought to an end, our planetary water supplies will continue to be subject to its increasingly polluting effects.

Flushing Sound: Pharma Must Pay To Toss Old Pills

July 25, 2012

After months of debate and controversy, a California county voted unanimously to require drugmakers to pay for the disposal of unused and expired prescription medicines. The move by Alameda County, which has been closely watched by other local governments around the country, is the first of its kindin the US and comes after the pharmaceutical industry lobbied to defeat the effort.
Read article at pharmalot.com

The patients ditching statins 'due to painful side effects of the cholesterol-lowering drugs that have left some bedridden'

July 21, 2012

Painful side effects from taking statins are far more common than experts thought, a study suggests. Patients reported coming off the cholesterol-lowering drugs after experiencing debilitating muscle pain and cramps, which in some cases left them unable to carry out everyday tasks or even bed-ridden.
Read article in the Daily Mail (UK)

Comment: Cholesterol-lowering drugs are one of the largest business segments of the global pharmaceutical drug business. This entire business is built on fear – the fear that cholesterol actually causes heart attacks. While the “cholesterol-scare” has become a gold mine for the Pharma Cartel, the economic burden of this business is ultimately carried by us, the people. To learn the facts about cholesterol and statins, click here. To read about Dr. Rath’s scientific discovery that coronary heart disease occurs for exactly the same reason that clinical (early) scurvy does – a deficiency of vitamin C in the cells composing the artery wall – click here.

Pfizer Loses Prempro Ruling, Must Pay $10.4 Million

July 21, 2012

Pfizer must pay $10.4 million in damages to a woman who blamed the company’s Prempro menopause drug for her breast cancer, an appeals court said.
Read article at bloomberg.com

Anemia drugs made billions, but at what cost?

July 20, 2012

For years, a trio of anemia drugs known as Epogen, Procrit and Aranesp ranked among the best-selling prescription drugs in the United States, generating more than $8 billion a year for two companies, Amgen and Johnson & Johnson. Even compared with other pharmaceutical successes, they were superstars. For several years, Epogen ranked as the single costliest medicine under Medicare: U.S. taxpayers put up as much as $3 billion a year for the drugs. The trouble, as a growing body of research has shown, is that for about two decades, the benefits of the drug — including “life satisfaction and happiness” according to the FDA-approved label — were wildly overstated, and potentially lethal side effects, such as cancer and strokes, were overlooked.
Read article in The Washington Post (USA)

Report: J&J will pay $2.2B in Risperdal settlement

July 19, 2012

Johnson & Johnson has agreed to pay as much as $2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal, according to a published report. The Wall Street Journal, which reported the settlement Thursday, said the settlement will include a $400 million criminal fine and that the final amount will depend on how many states accept the settlement.
Read article in the Houston Chronicle (USA)

Multiple Sclerosis Meds Fail To Slow Progression

July 18, 2012

Three medicines that are widely prescribed to combat multiple sclerosis failed to reduce the progression of the disabling disease in a newly released study. And the findings amount to a setback for three drugmakers whose treatments have collectively generated billions of dollars in annual sales for the past several years. The drugs include Avonex, which made by Biogen Idec; Betaseron, which is sold by Bayer, and the Rebif medication marketed by Merck KGaA.
Read article at pharmalot.com

Comment: Unlike the conventional medicine approach to disease, which focuses on controlling symptoms, Dr. Rath’s Cellular Medicine approach is based upon the scientific understanding that chronic deficiencies of vitamins, amino acids and other essential micronutrients are the primary cause of today’s most common chronic diseases. This innovative approach to human health is based on a new understanding of the basis of health and disease in the human body: health and disease are determined at the level of the millions of cells from which our bodies are built, and not at the level of organs. To read scientific studies showing how essential micronutrients can fight multiple sclerosis, click here and here.

Vast F.D.A. Effort Tracked E-Mails of Its Scientists

July 14, 2012

WASHINGTON – A wide-ranging surveillance operation by the Food and Drug Administration against a group of its own scientists used an enemies list of sorts as it secretly captured thousands of e-mails that the disgruntled scientists sent privately to members of Congress, lawyers, labor officials, journalists and even President Obama, previously undisclosed records show. What began as a narrow investigation into the possible leaking of confidential agency information by five scientists quickly grew in mid-2010 into a much broader campaign to counter outside critics of the agency’s medical review process, according to the cache of more than 80,000 pages of computer documents generated by the surveillance effort.
Read article in the New York Times (USA)

Man deformed in womb sues drugs giant for €55,000

July 13, 2012

A teacher born with no penis and his bladder outside his body is battling the German pharmaceuticals giant Bayer for €55,000 compensation. André Sommer, 35, needed nine operations and has to wear a urine bag because of birth defects he claims were caused by a pregancy-testing drug, Duogynon.
Read article in The Independent (UK)

IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly $1.2 Trillion By 2016

July 12, 2012

Following several years of slowing growth, the global market for medicines is poised to rebound from an expected low point of 3-4 percent growth in 2012 to 5-7 percent in 2016, according to a new forecast issued by the IMS Institute for Healthcare Informatics. The report, The Global Use of Medicines: Outlook through 2016, found that annual global spending on medicines will rise from $956 billion in 2011 to nearly $1.2 trillion in 2016, representing a compound annual growth rate of 3-6 percent.
Read press release at imshealth.com

Comment: As this press release shows, total global drug sales for the Pharma Cartel during 2011 were worth 956 billion dollars. To put this extraordinary amount of money into context, it represents a sum that exceeds the combined gross domestic product (GDP) of the world’s 120 poorest countries. Furthermore, by 2016, global sales are forecast to reach nearly 1.2 TRILLION dollars per year (i.e. 1,200 billion, or 1,200,000,000,000). It is worth remembering these facts the next time someone asks you to donate money to a charity for research into new drug treatments. After all, with astronomical sales figures like these, the "business with disease" is clearly not short of funds for research. For an analysis of the Pharma Cartel's global sales figures between 2003 and 2011, click here.

Merck Hid Evidence Of Vioxx Harm: Study

July 10, 2012

And so, the Vioxx saga continues. Nearly eight years after Merck withdrew the controversial painkiller over links to heart attacks and strokes, a new paper indicates the drugmaker hid evidence that Vioxx tripled the risk of cardiovascular death for more than three years before taking the pill off the market in 2004. During the same period, the paper in the American Heart Journal notes, Merck had regularly insisted such an increased did not exist.
Read article at pharmalot.com

Australian Pharma Balks At Disclosing Doc Data

July 5, 2012

Although drugmakers have gradually disclosed details of their relationships with physicians in the US, the pharmaceutical industry is resisting a similar effort in Australia, where revisions are being made to a voluntary code. Specifically, they are balking at providing names of individual doctors who receive payments and the specific amounts that are paid, according to The Conversation.
Read article at pharmalot.com

Medical Journals, Reprints And Publication Bias

July 3, 2012

It is no secret that reprints of studies published in medical journals are widely used as promotional tools by the pharmaceutical industry. And these reprints are also a welcome source of revenue for publishers. Of course, this has raised perennial questions about conflicts of interest, since the value of a large reprint order has the potential to influence whether a paper is accepted for publication. To explore such concerns, a group of researchers sought to determine whether industry funding is associated with high reprint orders. And a new analysis suggests an association does, indeed, exist.
Read article at pharmalot.com

Glaxo Agrees to Pay $3 Billion in Fraud Settlement

July 2, 2012

In the largest settlement involving a pharmaceutical company, the British drugmaker GlaxoSmithKline agreed to plead guilty to criminal charges and pay $3 billion in fines for promoting its best-selling antidepressants for unapproved uses and failing to report safety data about a top diabetes drug, federal prosecutors announced Monday. The agreement also includes civil penalties for improper marketing of a half-dozen other drugs.
Read article in the New York Times (USA)

Comment: Glaxo reported pre-tax profits of GBP 1.9bn ($3bn) during the three months to the end of December 2011 alone. For the whole of 2011, it reported a pre-tax profit of GBP 8.2bn ($12.9bn). As such, whilst this settlement is the largest ever involving a drug maker, the fact is that Glaxo can easily afford it.

EU's pharma patent court will be sited in London

July 2, 2012

One of the last pieces of the EU's unitary patent scheme fell into place late last week after the European Council agreed the locations of three unified patent courts. The central court will be located in Paris, while specialist courts will be set up in London and Munich. The London operation will deal primarily in patent cases related to the pharmaceutical and life sciences sectors, while Munich will deal with mechanical engineering and related fields.
Read article at pmlive.com (UK)

Comment: With these latest moves towards the finalization of a Brussels EU patent scheme, the work begun in the 1940s and 1950s by the Cartel’s Nazi patent expert, Carl Friedrich Ophuels, has almost been completed. To learn the shocking truth about the Nazi roots of the Brussels EU, click here.

Study suggests antipsychotic drugs during pregnancy linked to increased risk of gestational diabetes

July 2, 2012

A study that examined maternal use of antipsychotic drugs during pregnancy suggests that these medications may be linked to an increased risk of gestational diabetes, according to a report in the July issue of Archives of General Psychiatry.
Read article at medicalxpress.com

Roche Ordered to Pay $18 Million to Former Accutane Users

June 29, 2012

Roche Holding AG must pay a total of $18 million in damages to two former users of its Accutane acne drug who blamed the medicine for their bowel disease, a New Jersey jury ruled.
Read article at bloomberg.com

Wholesalers Are ‘Pill Mills’ For Painkillers

June 27, 2012

In a bid to curb the explosive abuse of prescription painkillers, West Virginia has filed lawsuits accusing 14 pharmaceutical wholesalers of “creating and profiting from the epidemic.” In strongly worded prepared remarks, West Virginia Attorney General Darrell McGraw called AmerisourceBergen and Cardinal Health, among others, “pill mills” that must pay for their “illicit actions.”
Read article at pharmalot.com

Comment: The term "pill mill" is used to describe a doctor, pharmacist, pharmacy, clinic or wholesaler whose primary function is the distribution of pharmaceutical narcotics for profit. Operating as middle-men between the Pharma Cartel and addicts, "pill mill" owners and operators are essentially drug dealers in white lab coats. Significantly, therefore, according to U.S. Federal Centers for Disease Control and Prevention statistics, nearly 15,000 Americans die every year from overdoses involving prescription painkillers — more than those who die from heroin and cocaine combined.

What Transparency? Amylin Hid Byetta Data

June 25, 2012

In a damning disclosure, an FDA official charges that Amylin Pharmaceuticals concealed a study that raised heart safety concerns about its Byetta diabetes drug and then hindered agency access to the data when it was discovered, TheStreet reports, citing newly released FDA documents. And later, Amylin execs purportedly lied to investors by failing to disclose that the Byetta study played a key role in an agency decision to reject the Bydureon follow-up treatment.
Read article at pharmalot.com

In Documents on Pain Drug, Signs of Doubt and Deception

June 24, 2012

A research director for Pfizer was positively buoyant after reading that an important medical conference had just featured a study claiming that the new arthritis drug Celebrex was safer on the stomach than more established drugs. “They swallowed our story, hook, line and sinker,” he wrote in an e-mail to a colleague. The truth was that Celebrex was no better at protecting the stomach from serious complications than other drugs. It appeared that way only because Pfizer and its partner, Pharmacia, presented the results from the first six months of a yearlong study rather than the whole thing.
Read article in the New York Times (USA)

Drug company Roche accused of not reporting possible drug side-effects

June 22, 2012

The European Medicines Agency said on Thursday it was investigating Swiss group Roche Holding AG after a routine inspection found it had failed to properly assess 80,000 cases of possible adverse drug reactions.
Read article at foxnews.com

Comment: The adverse drug reactions not reported by Roche are said to include 15,161 deaths. Other issues apparently identified include questions concerning around 23,000 adverse events related to evaluating and reporting to national regulators and 600 pertaining to clinical trials.

Test Subject Sues Pfizer for $1 Million

June 22, 2012

PORTLAND, Ore. (CN) - A woman claims in court that she suffered debilitating injuries requiring a double hip replacement after Pfizer canceled a drug test in which she was enrolled - without telling her that it called off the test for precisely the disease from which she was about to suffer. Candace Stewart sued Pfizer, Summit Research Network and Dr. James Bergthold, in Multnomah County Court. Stewart says she suffered osteonecrosis, also called bone death, in both hips, after agreeing to be part of the test study of Tanezumab, a monoclonal antibody against nerve growth factor, supposed to work as a painkiller.
Read article on the Courthouse News Service website (USA)

Cancer, a New View: Can You Believe it?

June 20, 2012

I learned, recently, about the father of a friend who committed suicide because he couldn't handle the painful side effects of radiation and chemo. It's tragic in every sense of the word that someone resolves their cancer but can't live with the agonizing, life-limiting challenges caused by the treatment. I wish there was more publicity given to the hard facts about long-term side effects of conventional cancer treatment.
Read article by Leigh Fortson on the Huffington Post website

Comment: The therapeutic goal of chemotherapy and radiation is to kill cancer cells by intoxicating the entire body. However, with the publication of Dr. Rath and Dr. Niedzwiecki’s latest book, ‘Victory Over Cancer!’, the end of this outdated ‘shotgun’ approach is finally in sight. A cancer-free world IS now possible, but it needs YOUR support to help bring it about. Click here to support the international initiative for a ‘Cancer Free World’ and commit to helping spread the information about science-based, natural health approaches in the fight against cancer in your town and country.

Why Cancer Treatment Is Fatally Flawed

June 20, 2012

Good Morning America co-anchor Robin Roberts' recent announcement that she had been diagnosed with myelodysplastic syndrome (MDS) -- a group of conditions in which the cells in the bone marrow are damaged -- certainly came as a shock to her fans. Just five years before she had, as she has said, "beaten breast cancer" and openly discussed her experience. What's more appalling, though, is the fact that her treatment for breast cancer, presumably involving chemotherapy and radiation, are both risk factors for MDS. In other words, the medical treatment she received to "beat" breast cancer may well be responsible for the life-threatening condition she now faces.
Read article on the Huffington Post website

Comment: As this article describes, the list of drugs that can cause myelodysplastic syndrome (MDS) is long and includes mechlorethamine (nitrogen mustard), etoposide, teniposide, chlorambucil, cyclophosphamide and doxorubicin -- all of which are commonly-used in chemotherapy. Tragically, therefore, most people still don't realize that cancer treatments can be as devastating and potentially deadly as the cancer itself. To read shocking extracts from the so-called "patient information leaflets" of chemotherapy drugs, click here.

Pfizer Paid $896 Million in Prempro Settlements

June 19, 2012

Pfizer Inc. (PFE) (PFE), the world’s largest drugmaker (PFE), said in a securities filing that it has paid $896 million to resolve about 60 percent of the cases alleging its menopause drugs caused cancer in women. Pfizer has now settled about 6,000 lawsuits that claim Prempro and other hormone-replacement drugs caused breast cancer, and it has set aside an additional $330 million to resolve the remaining 4,000 suits, according to a filing with the U.S. Securities and Exchange Commission.
Read article at businessweek.com

Comment: At the height of this litigation, Pfizer is reported to have faced more than 10,000 claims that its menopause drugs caused breast cancer. Significantly, therefore, Wyeth, the manufacturer of Prempro that became a division of Pfizer in 2009, was exposed in the New York Times in 2008 as having paid ghostwriters to produce medical journal articles favorable to the drug. Court documents released the following year showed that ghostwriters paid by Wyeth played a major role in producing 26 scientific papers backing the use of hormone replacement therapy in women. At least one of the ghostwritten articles was published even after a study found that Prempro raised the risk of breast cancer.

Immunity for Big Pharma

June 18, 2012

The Texas Supreme Court has given Big Pharma a license to defraud Texas patients. In a unanimous ruling that ignores the decision of a local jury and overturns a lower appellate court, the Supreme Court ruled that big drug companies have no responsibility to directly warn patients about the dangers of powerful pharmaceuticals. With doctors and nursing homes already shielded from accountability, this decision completes the medical industry trifecta of immunity by adding drug makers to the list. The decision is not surprisingly being hailed by pharmaceutical conglomerates, medical industry lobbyists, and other special interests.
Read article at texaswatch.org (USA)

Diabetes Drugs Avandia, Actos Linked to Vision Woes
They may raise risk of macular edema, researchers report

June 11, 2012

British researchers report that thiazolidinediones, diabetes medications that are used to help control blood sugar levels, may cause eye problems in those who take them. The drugs that fall into this group include Avandia and Actos, which have been tied to increased risk of heart attack in the case of Avandia and bladder cancer in the case of Actos.
Read article on the US News and World Report website

Statins shown to cause fatigue

June 11, 2012

In a study of more than 1,000 adults, researchers at the University of California, San Diego, found that individuals taking cholesterol-lowering statin drugs are more likely than non-users to experience decreased energy, fatigue upon exertion, or both.
Read article at medicalxpress.com

HK drug maker accused of destroying lake

June 8, 2012

A major Hong Kong-based drug maker has been dumping industrial waste and discharging sewage, severely damaging China's eighth largest freshwater lake in north China, according to a report in China Business News. The pollution continued even though United Laboratories International Holdings Ltd was cited by local authorities and told to clean the mess years ago, the report stated.
Read article at eastday.com (China)

Antidepressants, Autism & The Water Supply

June 7, 2012

Yet another study suggests that pharmaceuticals finding their way into the water supply may be linked to a troubling issue. A team of researchers has discovered that fish show autism-like gene expression after exposure to water containing antidepressants, such as Prozac and Effexor.
Read article at pharmalot.com

Comment: Evidence is growing worldwide that the pharmaceutical industry is polluting the environment and that drinking water supplies are now contaminated with measurable amounts of dangerous synthetic chemical drugs. A study published in 2009, for example, found that fish caught near wastewater treatment plants serving five major U.S. cities had residues of pharmaceuticals in them. Thus far, testing has revealed that at least 46 million Americans are drinking water contaminated with pharmaceuticals. Meanwhile, scientists in the UK have found cancer drugs in tap water and rising levels of antidepressant drugs in coastal waters which they fear could seriously upset the natural balance of the ecosystem and potentially damage the food-chain. The world’s highest drug levels in water are believed to occur in India, where 21 different active pharmaceutical ingredients – at 150 times the highest levels detected in the U.S. – have been found.

Low-dose aspirin use ups bleeding risk

June 6, 2012

In a new study, daily use of low-dose aspirin was found to be associated with an increased risk of major gastrointestinal or cerebral bleeding among nearly 200,000 individuals.
Read article in The Times of India

Study detects 'chemobrain' in EEG activity

June 4, 2012

A Cleveland Clinic study has detected significant changes in the electroencephalogram (EEG) brain activity patterns of patients receiving chemotherapy.
Read article at medicalxpress.com

Comment: The first chemotherapy drug was derived from ‘mustard gas’, a chemical warfare agent used in World War I as a weapon! Notably, therefore, derivatives of this deadly gas are still being used in cancer patients today as mechlorethamine, cyclophosphamide, chlorambucil and ifosfamide. As such, with chemotherapy drugs being amongst the most toxic substances known to man, it is hardly surprising that their infusion into the body can cause damage to the brain.

Diabetes drug increases risk of bladder cancer: study

June 1, 2012

A new study adds further weight to the argument that people who use the diabetes drug Actos are at higher risk of developing bladder cancer. A group of Montreal researchers is reporting that people with Type 2 diabetes who take the drug are more than 80 per cent more likely to develop bladder cancer than people who don’t. And for those who take it over a prolonged period, the risk is higher still.
Read article in the Vancouver Sun (Canada)

Women often not told about post-cancer infertility

May 29, 2012

Cancer treatment can sometimes lead to infertility, but young women are far less likely than young men to be informed of this, according to a Swedish study.
Read article at msnbc.com

Comment: Chemotherapy treatments for cancer are extremely toxic. To read shocking extracts from the "patient information leaflets" of these drugs, as published by the drug manufacturers themselves, click here. To support our campaign for a cancer free world, based on Dr. Rath’s scientific breakthrough in the natural control of cancer and more than a decade of pioneering research at our Institute in California, click here.

Prostate cancer screening report sparks debate among doctors, survivors

May 22, 2012

A controversial new report that recommends against routine prostate screenings has sparked a wide debate among doctors, cancer survivors and patients. The U.S. Preventive Services Task Force issued its final report on Monday, recommending against prostate-specific antigen (PSA) screening for prostate cancer for men of any age. The reason? Very few men actually need treatment to survive and the side effects from prostate cancer treatment do more harm than good, the task force said.
Read article and watch video news report at news.yahoo.com

Comment: The only beneficiary from the "overdiagnosis" of prostate cancer and its unnecessary treatment is the pharmaceutical ‘Business with Disease’ and its near-trillion dollar per year sales in patented chemical drugs.

French drugmaker on trial over weight-loss pill
At least 500 deaths thought to be caused by Mediator

May 14, 2012

French drugmaker Servier and its founder went on trial on Monday accused of misleading patients and authorities about a diabetes drug often prescribed for weight loss that officials blame for at least 500 deaths. The case, one of France's worst health scandals, has put authorities under scrutiny for allowing the sale of Mediator long after the medicine had been pulled in other European countries.
Read news report at reuters.com

Why Were Risky, Ineffectual Bone Drugs Approved, Some Are Asking

May 10, 2012

Like Vioxx, Merck's expensive "super aspirin" that caused thousands of cardiovascular events before being recalled, Merck's Fosamax, the first bisphosphonate bone drug, flew out of the FDA with only a six-month review. And like Vioxx, the true dangers of the drug class (that includes Fosamax, Boniva and Reclast) only surfaced after being "tested" on the guinea pig known as John Q Public. Now, people are asking why the bone drugs were ever approved.
Read article at foodconsumer.org

India probes charges of violations by drugs regulator

May 10, 2012

India's Health Ministry said Thursday it was examining charges that the government's top drug regulatory agency had colluded with pharmaceutical firms to approve drugs without proper clinical trials.
Read article at medicalxpress.com

FDA: Celgene Drug Revlimid Increases Risk Of Certain New Cancers

May 7, 2012

WASHINGTON – The Food and Drug Administration said certain patients treated with Celgene Corp.'s (CELG) cancer drug Revlimid have an increased risk of developing some new types of cancers.
Read article at foxbusiness.com

Comment: Almost half of the substances listed by the US government as ‘carcinogenic’ – i.e. cancer-causing – are pharmaceutical drugs prescribed for various diseases. However, given that one of the key strategies of the Pharmaceutical ‘Business with Disease’ is to expand its markets by causing new diseases with drugs, this should hardly be viewed as surprising. The drugs used in chemotherapy provide a particularly good example of this tactic as they are extremely toxic, with the result that many of them are well known to cause new cancers and new diseases – thus leading to the use of yet more drugs which in turn cause still further side effects. It’s a vicious circle and a license to print money for the pharmaceutical industry. To learn the facts about the drugs used in chemotherapy, click here.

How pain medication ups heart disease risk

May 3, 2012

After almost 13 years of study and intense debate, researchers have shed light on exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it. It has been almost eight years since Vioxx was withdrawn by Merck from the market, provoking an intense controversy about the role inhibitors of the enzyme COX-2 play in causing heart attacks and strokes. Since then, other drugs in the class from Pfizer, Novartis, and Merck have been withdrawn (Bextra); have failed to be approved (Arcoxia, Prexige); or have been retained on the market in the US with a “black box” warning on the label (Celebrex).
Read article at zeenews.india.com

Physician, heal thyself

May 2, 2012

As inflation spirals in Pakistan, the one most seriously affected is the common man. Decent healthcare is said to be beyond the reach of the overwhelming majority. But one man’s meat is another man’s poison and some are benefiting from the misery of the poor. One beneficiary of this state of affairs is the pharmaceutical sector.
Read article at dawn.com (Pakistan)

Comment: With some of its physicians now hand in glove with the Pharma Cartel and exploiting the country’s poor, Pakistan is rapidly becoming subject to the same corrupting principles that the Business with Disease has already used to fuel its multi-billion dollar growth throughout much of the rest of the world.

One Nation Under Drugs: How the FDA Is Sabotaging Your Health and the Environment

April 30, 2012

As a medicinal chemist, I tried to ignore my suspicion that an insidious and deliberate conspiracy to get each and every American hooked on drugs, while at the same time bankrupting them, existed between Big Pharma and the Food and Drug Administration (FDA). I enjoyed my work. Drug design paid well and kept me comfortably isolated in a high-tech lab, fully equipped to help me bend and twist matter at will. The last thing I wanted to think of was a plot designed to sabotage health and wealth-while causing untold ecological damage-using my chemistry skills. But over time, experience confirmed my suspicion as fact and revealed something even scarier.
Read article by Shane Ellison, M.S. at ecohearth.com (USA)

Anti-Depressants Likely Do More Harm Than Good, Study Suggests

April 24, 2012

Commonly prescribed anti-depressants appear to be doing patients more harm than good, say researchers who have published a paper examining the impact of the medications on the entire body.
Read article at sciencedaily.com

Drugmakers Refuse To Back Down Over ALEC

April 13, 2012

As more corporations flee the American Legislative Exchange Council – better known as ALEC – in response to a growing pressure campaign, the pharmaceutical industry is stubbornly holding its ground. In recent days, Coca-Cola, Kraft Foods, PepsiCo, Wendy’s, Elseiver and McDonald’s, as well as the Bill and Melinda Gates Foundation, have left or agreed to leave the controversial organization that quietly works to craft state laws that favor corporate interests. Drugmakers, however, are refusing to join the exodus. These include GlaxoSmithKline, Johnson & Johnson, Bayer and Pfizer, as well as the Pharmaceutical Research and Manufacturers of America trade group, which is known as PhRMA.
Read article at pharmalot.com

J&J Is Fined $1 Billion Over Risperdal Marketing

April 11, 2012

In a huge blow to Johnson & Johnson, an Arkansas judge has fined the healthcare giant and its Janssen subisdiary more than $1.1 billion one day after a jury found the companies downplayed and hid risks – notably, diabetes and weight gain – associated with its Risperdal antipsychotic drug.
Read article at pharmalot.com

Pharma majors block better deal for victims

April 10, 2012

Victims of clinical trials in India will continue to be given a raw deal, as drug companies are calling the shots in the panel set up by the Government to decide on the payment of compensation to such victims. In what seems to be a clear case of conflict of interest, of the 17 stakeholders who participated at a meeting called by the Drug Controller General of India (DCGI) on March 18 to deliberate on the guidelines for payment of compensation to the victims of clinical trials, as many as 10 represented drug manufacturing firms.
Read article at dailypioneer.com (India)

EMA Committee Chair Suddenly Resigns

April 5, 2012

The fallout from the Mediator scandal continues. The chair of the European Medicines Agency’s Committee for Medicinal Products for Human Use, which approves new drugs, unexpectedly resigned yesterday. And an EMA spokesman tells us the departure was linked to his role as a scientific advisor to the French healthcare regulator, Agence Francaise de Securite Sanitaire des Produits de Sante, or AFSSAPS.
Read article at pharmalot.com

Comment: Despite warnings dating back as early as 1998, a deadly pharmaceutical drug, Mediator, was prescribed to 5 million French people. Successive French health ministers ignored scientific advice that the drug – produced by the French pharmaceutical giant, Servier, a company well known for its cult of secrecy and close relations with French politicians – was at best useless, and at worst highly dangerous. Notably, therefore, it emerged that French President Nicolas Sarkozy – who, in 2004, coerced the marriage between French pharmaceutical dwarf Sanofi and Swiss/German drug giant Aventis/Hoechst – previously worked for Servier as a lawyer. Now suspected to have killed up to 2,000 people, serious questions as to how Mediator was officially approved, and subsidized for 33 years by the French health service, remain unanswered.

Routine mammograms may result in significant overdiagnosis of invasive breast cancer

April 2, 2012

New Harvard School of Public Health (HSPH) research suggests that routine mammography screening—long viewed as an essential tool in detecting early breast cancers—may in fact lead to a significant amount of overdiagnosis of disease that would otherwise have proved harmless. Based on a study of women in Norway, the researchers estimate that between 15% and 25% of breast cancer cases are overdiagnosed.
Read article at medicalxpress.com

Comment: Ultimately, the key beneficiary from the overdiagnosing of breast cancer is the multi-billion dollar pharmaceutical ‘business with disease’, which has a vested financial interest in as many patients as possible being treated with its patented chemotherapy drugs. Notably therefore, whilst the early detection of health problems is very important in curtailing the progress of, or eliminating, disease at its onset, in recent years, many doctors – and especially radiologists – have become concerned with the overuse of diagnostic techniques such as X-rays, ultrasounds, MRI and CT scans. To learn how to use diagnostic technologies wisely and for the benefit of your health, click here.

Osteoporosis drugs increase risk of eye disease, says Canadian study

April 2, 2012

New Canadian research shows that osteoporosis drugs can increase the risk of serious eye disease.
Read article in the Toronto Star (Canada)

Whistleblower now reluctant biotech safety spokeswoman

April 1, 2012

Former Pfizer Inc. molecular biologist Becky McClain calls herself a "reluctant activist" now that she has become a national spokeswoman for biotech safety after winning a $1.37 million judgment two years ago against her former employer. "I'm a scientist," the Deep River resident said. "I'm not schooled in public speaking." But McClain, who won a jury award on April 1, 2010, against Pfizer after being fired following a series of safety complaints and what she says was exposure to a novel virus at the pharmaceutical giant's Groton laboratories, has been taking speaking engagements around the country to inform the public about the dangers of unregulated biotech laboratories.
Read article at theday.com (USA)

States Battle Over Immunity For Drugmakers

March 30, 2012

Once again, the North Carolina legislature is contemplating a bill that would protect drugmakers and those selling medications from liability in lawsuits. The legislation would make it harder for North Carolina consumers to recover damages from harm allegedly suffered by a prescription drug than citizens in any other state in the US, except Michigan.
Read article at pharmalot.com

Big Pharma spends over €40 million per year lobbying in the EU, dwarfing public health NGOs

March 28, 2012

New research reveals that the pharmaceutical industry lobby is spending more than €40 million annually to influence decision making in the European Union (EU) – of which nearly half is spent by drug manufacturers on in-house lobbyists.
Read article on the Corporate Europe Observatory website

Comment: As registration to the Brussels EU’s so-called “Transparency Register” is voluntary, the construct’s drug companies are able to avoid declaring their full lobbying expenditures. Notably, therefore, the report suggests that, if recorded properly, expenditure on lobbying by the Pharma Cartel could be shown to be as high as €91 million annually, which would be comparable with the amount it declares on lobbying in the United States.

Judge bars import of drug used in death penalty

March 28, 2012

A judge on Tuesday barred authorities from importing an anesthesia drug used in carrying out death sentences because the Food and Drug Administration never approved the drug for use in the United States, and he ordered supplies be confiscated. A group of death row inmates had sued the FDA last year over improperly allowing shipments into the country of sodium thiopental, a sedative used as the first of three drugs administered in carrying out executions.
Read news report at reuters.com

Comment: A particularly notable aspect of this lawsuit relates to the fact that, in seeking to have the case dismissed, the FDA deliberately departed from its longstanding practice of not allowing unapproved drugs into the United States. As such, whilst the banner on the FDA’s website disingenuously claims that the agency is “Protecting and Promoting” the health of American citizens, the reality would appear to be very different. Through exhibiting what the judge described as a “callous indifference to the health consequences of those imminently facing the executioner's needle,” the FDA is knowingly perpetuating the drug industry’s already long history of supplying chemicals for killing prisoners. With the industry already having been proven to have supplied the substances that killed tens of thousands of prisoners at the Auschwitz WWII concentration camp, it is high time that not only the companies profiting from selling chemicals for use in executions, but also their stakeholders in government agencies, are publicly exposed.

Heart-damaging side effects of cancer drugs under-reported in studies

March 26, 2012

The under-reporting of the possible side effects of heart damage from cancer drugs puts patients at an increased risk for heart failure, according to two researchers at the Stanford University School of Medicine.
Read article at medicalxpress.com

Comment: The patented chemical drugs used in the orthodox treatment of cancer kill body cells indiscriminately and cause severe side effects in patients. This is in sharp contrast to vitamin C which, in a study published in the prestigious Proceedings of the National Academy of Sciences of the United States of America in September 2005, has been confirmed by scientists at the US National Institutes of Health to kill cancer cells selectively. In this respect, the work of these US government scientists confirms the cancer discoveries of Dr. Rath and his research team who, over three years earlier, had presented their findings at the 19th Annual Miami Breast Cancer Conference in Florida and published details of their scientific breakthrough in ‘USA Today’. To learn more about safe and effective natural health approaches to cancer treatment that have been shown to block ALL key mechanisms that make it a deadly disease, click here.

Antidepressants give drugmakers the blues

March 23, 2012

The development of a novel antidepressant ground to a halt this week when researchers found it did not make patients feel any better than the pills they were already taking.
Read news report at reuters.com

Comment: Antidepressants are well known to be connected with a wide range of serious and life-threatening side effects, including hypertension in pregnancy, narrowed arteries, an increased risk of cardiovascular disease and stroke, suicidal behaviour and even cancer. As such, bearing in mind that one of the largest studies of antidepressant drugs found they have no clinically significant effect, not only has the Drug Cartel been misleading people about their effectiveness, the health and lives of millions of people have been ruthlessly exploited for profit.

A Bizarre Outcome on Generic Drugs

March 23, 2012

Dozens of suits against drug companies have been dismissed in federal and state courts because of a decision by the Supreme Court last year that makes it virtually impossible to sue generic manufacturers for failing to provide adequate warning of a prescription drug’s dangers. This outrageous denial of a patient’s right to recover fair damages makes it imperative that Congress or the Food and Drug Administration fashion a remedy.
Read editorial in the New York Times (USA)

Antidepressants May Soar Hypertension Risk in Pregnant Women

March 23, 2012

As per recent reports, it has been found by a group of researchers at the Université de Montreal, Quebec, Canada that antidepressants that are often prescribed to pregnant women may cause the problem of hypertension in them.
Read article at frenchtribune.com

GSK confirms $800 million UK manufacturing investment

March 22, 2012

GlaxoSmithKline, Britain's biggest drugmaker, confirmed plans on Thursday to invest more than 500 million pounds ($792 million) in manufacturing in Britain as it selected a north of England location for a previously announced biotech plant. The news - though expected - is a boost for Prime Minister David Cameron, who has made wooing the pharmaceuticals industry a priority in the wake of Pfizer's 2011 decision to shutter its giant research centre in Sandwich, southern England.
Read Reuters news report at yahoo.com

Comment: Given that Cameron has already dictatorially ruled out a referendum on Britain’s membership of the Brussels EU – despite the fact that a majority of the country’s voters want a vote on this undemocratic construct – this latest development makes it overwhelmingly clear where his ultimate loyalties now lie. To understand the close relationship between the Pharma Cartel and the Brussels EU, and learn about the true history of Europe that has been hidden from its citizens, click here.

Experts challenge FDA over approval for new dose of Alzheimer's drug

March 22, 2012

Approval for a new dose of a best-selling Alzheimer's drug "breached the FDA's own regulatory standard" and has led to "incomplete and distorted messages" about the drug, warn experts in the British Medical Journal today.
Read article at medicalxpress.com

Pain relievers could be causing high BP

March 21, 2012

Many common over-the-counter and prescription drugs lead to hypertension, which is a major risk factor for stroke, heart attack, and aneurisms, a new study has revealed.
Read article on the Times of India website

Generic Drugs Prove Resistant to Damage Suits

March 20, 2012

Debbie Schork, a deli worker at a supermarket in Indiana, had to have her hand amputated after an emergency room nurse injected her with an anti-nausea drug, causing gangrene. She sued the manufacturer named in the hospital’s records for failing to warn about the risks of injecting it. Her case was quietly thrown out of court last fall. That result stands in sharp contrast to the highly publicized case of Diana Levine, a professional musician from Vermont. Her hand and forearm were amputated because of gangrene after a physician assistant at a health clinic injected her with the same drug. She sued the drug maker, Wyeth, and won $6.8 million. The financial outcomes were radically different for one reason: Ms. Schork had received the generic version of the drug, known as promethazine, while Ms. Levine had been given the brand name, Phenergan.
Read article in the New York Times (USA)

Attorney: Michigan Department of Human Services harasses family of 10-year-old cancer patient

March 13, 2012

Jacob Stieler, a year after being diagnosed and apparently beating a rare form of bone cancer, is playing basketball for the first time and rushing down mountain ski hills, moments the 10-year-old’s parents thought they might not ever see. But that physical strength, and a series of clear blood tests and PET scans, isn’t enough to convince the state to let the Marquette County family reject doctor-recommended treatment of his Ewing sarcoma, the family’s attorney said Tuesday. The state has filed an appeal of an Upper Peninsula judge’s dismissal of a medical neglect claim against Jacob’s mother and father, Erin and Ken Stieler. The state Department of Human Services is asking the appellate panel to send the case to a trial that could force the 10-year-old to undergo follow-up care that includes six weeks of radiation therapy and six months of chemotherapy.
Read article at mlive.com (Michigan, USA)

Comment: Following a judge having previously dismissed charges of medical abuse against Jacob’s parents after they discontinued his chemotherapy treatments, it is clear that the political and medical stakeholders of the “pharmaceutical business with disease” remain intent upon going to almost any lengths to enforce the carrying out of toxic drug treatments upon him. This is despite his currently being cancer-free and the fact that the intravenous chemicals they want to compel him to endure can cause the development of additional cancers. Increasingly, however, the facts about chemotherapy are becoming more widely known and parents around the world are questioning both the safety and the efficacy of these dangerous drugs. To learn about natural health approaches to the treatment of cancer that have been shown to block all key mechanisms that make it such a deadly disease, click here.

Britain's shadow government: unelected, unbalanced and unaccountable

March 12, 2012

Democracy itself is being undermined by publicly funded agencies crawling with conflicts of interest and devoid of scrutiny
'From any single perspective', Bertrand Russell said, "power always seems to be elsewhere". This article is about one of those elsewheres. It is about the network of unelected committees, boards and commissions, operating below the public radar, through which governments pursue the aims that weren't disclosed in their manifestos. The people they appoint are an index to the interests they serve. To list them is to expose the gulf between what a government claims to be and what it is.
Read article by George Monbiot in The Guardian (UK)

Comment: At the time of writing, the Board of Britain’s Medicines and Healthcare Products Regulatory Agency (MHRA) contains retired senior executives from drug companies AstraZeneca and Merck Sharp & Dohme. Similarly, its Executive Board contains a former employee of Glaxo, DuPont and DuPont Pharmaceuticals who is currently an employee of Bristol-Myers Squibb; a former employee of Glaxo Wellcome and GlaxoSmithKline; and a former employee of SmithKline Beecham. Continuing this pattern, the council members on the country’s Medical Research Council (MRC) include representatives of Sanofi Pasteur and Pfizer, whilst its Global Health Group and Translational Research Group both have members from GlaxoSmithKline. Notably therefore, as long ago as 1997, Dr. Rath openly described the drug industry as the “biggest obstacle to world health.” His words remain just as true today as they were back then. Promisingly however, since 1997, in a strong sign that global awareness of this issue is growing, numerous books have been published describing the devastating impact the drug industry has on people and societies around the world. To learn more, click here.

Are asthma inhalers linked to birth defects? Thousands of pregnant women at centre of inquiry into health problems in babies

March 11, 2012

Thousands of pregnant women taking prescription drugs for asthma, epilepsy, diabetes and depression are at the centre of a major inquiry into birth defects and health problems in babies. Asthma inhalers, man-made insulin, new anti-epileptics and Prozac-style anti-depressants called SSRIs, are being probed in the Europe-wide study of nearly four million births.
Read article in the Daily Mail (UK)

Takeda Hid Actos Links To Cancer: Whistleblower

March 9, 2012

Takeda Pharmaceuticals may wish that Helen Ge was never hired as a consultant. She has now filed two whistleblower lawsuits alleging the drugmaker knowingly hid adverse events about various drugs. One lawsuit involved the Uloric gout treatment, which we recently reported (read here). Yet another concerns the Actos diabetes drug and a failure to report instances of bladder cancer and congestive heart failure.
Read article at pharmalot.com

Death magnifies Pradaxa hemorrhage concerns

March 6, 2012

The death of an elderly man from a massive brain hemorrhage after a routine fall suggests that bleeding complications from Boehringer Ingelheim's Pradaxa blood clot preventer are largely irreversible, according to the Journal of Neurosurgery.
Read news report at reuters.com

Revealed: How chemists and drug firms are coining it in on the back of Scotland's methadone programmes

March 1, 2012

Chemists and drug firms are raking in millions on the back of methadone addicts’ suffering, the Record can reveal today.
Read article on The Daily Record website (Scotland/UK)

Forcing Pharma To Dispose Of Unused Meds

February 29, 2012

A county in California took a big step closer yesterday to becoming the first in the nation to require drugmakers to dispose of unused and expired pharmaceuticals that are contaminating drinking water and putting youngsters and seniors at risk. In a 4-to-0 vote, the Alameda County Board of Supervisors approved a plan that now requires a final vote next month, The Oakland Tribune writes.
Read article at pharmalot.com

Big Pharma's shame: emerging markets bribery

February 28, 2012

In recent years, Big Pharma has forked out billions of dollars to settle scandals involving improper promotion of medicines in the United States. Now bribes paid to foreign doctors and other state employees are shaping up as the next major legal liability threat for the industry. A Reuters examination of U.S. Securities and Exchange Commission (SEC) filings by the world's top 10 drug companies has found that eight of them recently warned of potential costs related to charges of corruption in overseas markets.
Read article at msnbc.com

Sleeping pills may be as dangerous as smoking cigarettes, says lead author of new report

February 28, 2012

Hundreds of thousands of people who take sleeping pills just twice a month are nearly four times more likely to die prematurely, according to new research. The study, published in the journal BMJ Open, analysed 10,500 people taking a wide-range of sleeping pills, including tamazepam and diazepam.
Read article in the Daily Telegraph (UK)

'Chemo brain' may last and last

February 27, 2012

Chemotherapy patients have long complained of the mental fog that tends to accompany treatment, but a new study suggests that certain combinations of chemo drugs may have long-term effects on cognition.
Read article in the Los Angeles Times (USA)

Comment: The chemicals used in so-called "chemotherapy" are extremely toxic. To read shocking extracts from the "patient information leaflets" of these drugs, as published by the drug manufacturers themselves, click here. To learn about safe and effective natural health approaches to cancer treatment that have been shown to block ALL key mechanisms that make it a deadly disease, click here.

Cocktail of Popular Drugs May Cloud Brain

ebruary 27, 2012

Many people are unaware that dozens of painkillers, antihistamines and psychiatric medications — from drugstore staples to popular antidepressants — can adversely affect brain function, mostly in the elderly. Regular use of multiple medications that have this effect has been linked to cognitive impairment and memory loss.
Read article in the New York Times (USA)

Dementia 'chemical cosh' warnings

February 24, 2012

Experts have found more evidence that prescribing dementia patients "chemical cosh" drugs increases their risk of early death.
Read article in the Belfast Telegraph (Northern Ireland)

'Grief is not a mental illness that should be treated with pills': Doctors hit back at creeping medicalisation of life events
Backlash follows the American Psychiatric Association's reclassification of grief as a mental illness

February 17, 2012

Grief is not a mental illness that should be treated with anti-depressants, experts say. In an unsigned editorial in the influential medical journal The Lancet, experts argue that grief does not require psychiatrists and that 'legitimising' the treatment of grief with antidepressants 'is not only dangerously simplistic, but also flawed.'
Read article in the Daily Mail (UK)

Whitney Houston found in bath with prescription drugs nearby, latest reports claim

February 12, 2012

Whitney Houston was found in the bath with prescription drugs nearby, latest reports claim as the death of the singer prompts a worldwide outpouring of grief. Celebrity websites are claiming that the 48-year-old may have drowned in the bath and that while there were no illegal drugs in her room there were pills nearby.
Read article in the Daily Telegraph (UK)

Comment: As with the deaths of Michael Jackson and Heath Ledger before her, it seems possible that the tragic and untimely passing of Whitney Houston may turn out to be yet another sobering reminder of the life-threatening dangers of patented synthetic drugs. If so, then any subsequent arguments as to whether or not these toxic substances were prescribed by physicians essentially miss the point: Dangerous pharmaceuticals are not made safer just because they might have been obtained via a physician's prescription pad. Moreover, with its total annual global sales now approaching 1 trillion dollars, the grim reality is that the Pharma Cartel has a vested financial interest in users becoming addicted to its products.

Glaxo studies traditional Chinese medicine

February 12, 2012

Scientists from GlaxoSmithKline are to study how traditional Chinese medicine can be applied to modern drugs as part of a revamp of the company’s research and development. Britain’s biggest drug maker last week unveiled the outcome of a review of its 38 groups of scientists, known as Discovery Performance Units (DPU), saying it would close three units and open four. The Sunday Telegraph can reveal the new units will look at traditional Chinese medicines, investigating how their principles can be applied to making new, synthetic, molecules.
Read article in the Daily Telegraph (UK)

Comment: The near-trillion dollar a year profits of the pharmaceutical industry are based on the patenting of new synthetic molecules. The patents on these chemicals essentially allow drug companies to arbitrarily define their profits. Natural herbal-based medicines, on the other hand – given that they can’t be patented – are of no interest to the pharmaceutical industry. Instead, they are studied with the intention of producing new, synthetic versions of their key constituent molecules and then marketing these as multi-billion dollar patented drugs.

Psychologists fear US manual will widen mental illness diagnosis

February 9, 2012

Hundreds of thousands of people will be labelled mentally ill because of behaviour most people would consider normal, if a new edition of what has been termed the psychiatrists' diagnostic bible goes ahead, experts are warning.
Read article in the Guardian (UK)

Comment: The Diagnostic and Statistical Manual of Mental Disorders (DSM) is published by the American Psychiatric Association and contains symptoms and other criteria for diagnosing mental disorders. It is widely used internationally for diagnosis and treatment of psychological ailments and is considered as the psychiatrists’ bible. Currently, the DSM is being updated for 2013 publication with significant changes and modifications defining the diagnoses. For example, according to suggested changes in the upcoming fifth edition, a shy child, a defiant teen, or a grieving relative would be considered a psychiatric patient for treatment. The DSM was first compiled in 1952 and contained 107 disorders. This number has increased to 365 disorders in the most recent revision in 2000. This represents more than a 200% increase. As such, either the number of mental disorders in the population is inexplicably and dramatically increasing, or the slightest deviation from the so-called ‘normal’ is being diagnosed as a psychiatric disease. Without any doubt, the only beneficiary from these latest changes and modifications defining mental disorders is the pharmaceutical business with disease.

'Fen-phen' derived drug responsible for thousands of hospitalizations and deaths in France

February 9, 2012

A new study published in the journal Pharmacoepidemiology & Drug Safety reveals that benfluorex, a fenfluramine derivative drug used in France under the name Mediator, is likely responsible for thousands of hospitalizations and deaths over a 30 year period.
Read article at medicalxpress.com

Brown University, A Paxil Study And Retractions

February 6, 2012

For the past few years, an effort has been under way by a pair of academics to retract a study about the Paxil antidepressant in the Journal of the American Academy of Child and Adolescent Psychiatry that concluded the GlaxoSmithKline pill was “generally well tolerated and effective for major depression in adolescents.” Why? Since then, the 2001 paper has been discredited amid charges that primary and secondary outcomes were conflated, selective results were reported and ghostwriting was involved (see this).
Read article at pharmalot.com

J&J Hid Risperdal Studies to Boost Drug Sales, Lawyer Says

February 6, 2012

Johnson & Johnson hid studies showing its Risperdal anti-psychotic drug caused diabetes to protect billions of dollars in sales, a lawyer said in the first personal-injury claim over the medication to go to trial.
Read article at businessweek.com

Indigestion drugs taken by millions linked to hip fractures

February 1, 2012

Common indigestion drugs taken by millions of people may increase the risk of a hip fracture by a third, a study has found.
Read article in the Daily Telegraph (UK)

Why is “Hot Chemo” an Acceptable Cancer Treatment—But IV Vitamin C is “Too Far Out There”?

January 31, 2012

Patients liken hot chemotherapy to “being filleted, disemboweled, and then bathed in hot poison.” Best patient care, or merely the biggest moneymaker? According to the New York Times, hot chemotherapy, which couples extensive abdominal surgery with blasts of heated chemotherapy to the abdominal cavity and its organs, was once a niche procedure used mainly against rare cancers of the appendix. Most academic medical centers shunned it. Now it’s being offered to patients to treat more common colorectal or ovarian cancers. Dr. David P. Ryan, clinical director of the Massachusetts General Hospital Cancer Center, says there is little evidence that it really works and “has almost no basis in science.”
Read article on the Alliance for Natural Health (USA) website

Comment: In whatever form it is administered, chemotherapy is extremely toxic. Notably, therefore, what makes its use even worse is the fact that for many types of cancer – including prostate cancer, skin cancer (melanoma), bladder cancer, kidney cancer, pancreatic cancer and others – it is already established that chemotherapy does not prolong the life of cancer patients at all. In short: Patients with these types of cancer who received chemotherapy have essentially been shown to have the same limited life expectancy as those who didn’t. To learn about safe and effective natural health approaches to cancer that have been shown to block ALL key mechanisms that make it a deadly disease, click here.

Takeda Hid Harmful Drug Interactions: Consultant

January 31, 2012

A former safety consultant to Takeda Pharmaceuticals has accused the drugmaker of deliberately failing to inform physicians that some of its medicines can interact poorly with other drugs and cause serious adverse events.
Read article at pharmalot.com

Experts want suicide risk warning on ADHD drug

January 30, 2012

Children who take a common drug for attention deficit disorder should be warned about the risk of suicidal thoughts, U.S. pediatric health advisers said on Monday. Several members of an advisory committee to the Food and Drug Administration asked the agency to change the label for Focalin, an attention deficit medicine made by Swiss drugmaker Novartis AG, to reflect this risk.
Read news report at reuters.com

Surprise! James Murdoch Leaves The Glaxo Board

January 27, 2012

Months after we asked whether James Murdoch should remain on the GlaxoSmithKline board (back story), the embattled scion of the Murdoch media empire has decided not to stand for re-election at the upcoming annual shareholder meeting to be held this May. At least, that is the wording in an official statement released this morning by the drugmaker. His three-year stint as a non-executive director has been under a cloud ever since a scandal erupted over charges that various employees in the Murdoch media empire in the UK hacked into phones belonging to families of murder victims, terror victims, police and politicians.
Read article at pharmalot.com

Spain Plans Budget Law as Drug Firms Owed $8.4 Billion by States

January 26, 2012

Spain pledged to set spending limits for regional governments in a new law tomorrow as the country’s pharmaceutical lobby said the regions owe companies $8.4 billion for drugs.
Read article at bloomberg.com

Comment: Given that Spain had reduced its prescription drugs bill by a record 8.8% during 2011 but still ended up in debt to the Pharma Cartel, this news story illustrates perfectly the way in which indebted European countries are being forced still further into bankruptcy as a result of their national economies being continually drained by the fraudulent “Business with Disease”.

Statin Drugs Shown to Increase Risk of Diabetes Significantly—Yet the Media Scramble to Protect the Drugs’ Reputation

January 24, 2012

Statins are taken by one in four Americans over the age of 45, even though diet can fix high cholesterol quicker and more safely. Here’s new evidence of the drugs’ dangers. A University of Massachusetts Medical School study has found that statins significantly increase risk of type 2 diabetes among postmenopausal women—an increased rate of 48% compared to those not on cholesterol-lowering drugs. The data comes from the massive Women’s Health Initiative, which surveyed 161,808 women.
Read article on the Alliance for Natural Health (USA) website

Challenging Medical Ghostwriting in US Courts

January 24, 2012

Despite growing concern about medical ghostwriting, pharmaceutical companies, universities, medical journals, and communication companies employing ghostwriters have thus far failed to adequately stem the problem. As a result, some commentators have proposed that legal remedies could be sought by patients harmed by drugs publicized in ghostwritten papers.
Read essay by Xavier Bosch et al. at plosmedicine.org

Pharma Fights Effort To Dispose Of Unused Meds

January 23, 2012

For the past few years, a growing effort has been made to safely dispose of unused prescription drugs lingering in medicine cabinets and dresser drawers. Flushing medications down the toilet can cause environmental problems, such as tainting drinking water supplies (see this). And leaving drugs, notably painkillers, around the house can also lead to abuse and overdose by teens and adults, who sometimes sell pills. To combat the problem, a state senator in Washington plans to try - for a fourth time - to introduce legislation that would create a disposal program. And the plan, which is a modeled on a similar effort in Vancouver involving drop-offs at local pharmacies, would require drugmakers to pony up some funds to cover the cost. However, the pharmaceutical industry is, once again, fighting the program, as InvestigateWest reports.
Read article at pharmalot.com

J&J Must Face Lawsuits Over OTC Motrin Labeling

January 23, 2012

In a defeat for Johnson & Johnson, a federal judged ruled the drugmaker will have to defend against lawsuits charging it failed to properly warn that its over-the-counter Motrin pain reliever can cause Stevens-Johnson Syndrome and a deadlier form of the disease known as Toxic Epidermal Necrolysis. The judge refused to dismiss two lawsuits brought by parents who claim their children were harmed.
Read article at pharmalot.com

EMA Probes Novartis MS Pill Over Deaths

January 20, 2012

One month after Novartis initiated an investigation into a death tied to its new Gilenya pill for multiple sclerosis, the European Medicines Agency has now launched its own probe after receiving reports of up to 11 deaths among patients who took the medication.
Read article at pharmalot.com

Merck to settle Canada Vioxx suits for up to C$37M
Merck makes deal to settle Canadian Vioxx lawsuits for up to C$37 million, admits no liability

January 19, 2012

Drugmaker Merck & Co. said Thursday that it has reached a deal to settle all lawsuits in Canada over its recalled painkiller Vioxx, for up to 36.9 million Canadian dollars ($36.5 million).
Read Associated Press news report at yahoo.com

J&J Pays $158M To Settle Risperdal Lawsuit In Texas

January 19, 2012

Just one week after a closely watched trial began in an Austin, Texas, courtroom, Johnson & Johnson has agreed to pay $158 million to settle a lawsuit filed by the state attorney general, who charged the Janssen pharmaceutical unit orchestrated a controversial program that was allegedly designed to boost the use of the Risperdal antipsychotic in the public sector throughout the country. A whistleblower lawsuit filed in 2004 described how J&J surreptitiously created and funded TMAP, or the Texas Medication Algorithm Project. TMAP relied on various state officials and academics to develop and sell the program as a policy tool, according to the lawsuit, which was joined in 2006 by the Texas state attorney general Greg Abbott
Read article at pharmalot.com

Effects of Tamiflu still uncertain, warn experts, as Roche continues to withhold key trial data

January 18, 2012

Two years after pharmaceutical giant Roche promised the BMJ it would release key Tamiflu trial data for independent scrutiny, the safety and effectiveness of this anti-influenza drug remains uncertain, warn experts today. A new report by the Cochrane Collaboration says Roche's refusal to provide full access to all its data leaves critical questions about how well the drug works unresolved. A BMJ investigation, published to coincide with today's report, also raises serious concerns about access to drug data, the use of ghost writers in drug trials, and the drug approval process.
Read article at medicalxpress.com

Comment: Studies with Tamiflu conducted in children and the elderly have shown a reduction in the length of illness of only 1 day, with its reported side-effects including nausea; vomiting; headaches; diarrhoea; abdominal pain and dangerous psychiatric side effects. Notably, therefore, the official World Health Organization guidance on Tamiflu issued in 2004, which urged governments to stockpile the drug, was authored by scientists who had previously received payment from its manufacturer, Roche.

Cancer Drugs Could Cause Tumours To Spread, Rather Than Preventing Them, Warns Study

January 18, 2012

Cancer drugs that are designed to shrink tumours by cutting off the supply to their blood may be doing the opposite and helping them spread to other parts of the body, a study has warned.
Read article in the Huffington Post
Comment: Through the formation of new blood vessels – a process known as angiogenesis – tumours are able to feed and expand. A key mechanism of cancer development, drug companies are currently spending hundreds of millions of dollars to find synthetic inhibitors of this process that they can patent and market as drugs. Significantly, therefore, unlike drugs, micronutrients can decrease the formation of new tumour blood vessels safely, effectively and naturally. To learn more, read chapter III of Dr. Rath and Dr. Niedzwiecki’s new book, “Victory Over Cancer!”.

Prescription medication 'increases falls in all ages'

January 17, 2012

People who take two or more prescription drugs could be twice as likely to take a serious fall regardless of their age, research suggests.
Read article in the Daily Telegraph (UK)

New 'smart' pill tells patients when drugs dose due

January 17, 2012

A new “intelligent” pill that tells patients how to better follow doctors' orders and take medication properly is to go on sale in Britain within months, it has been announced. The tiny edible microchip records precise details of medication programmes through a monitoring “receiver” patch attached to patients' shoulder or arm.
Read article in the Daily Telegraph (UK)

Comment: The pharmaceutical industry portrays itself as an industry fighting to prevent and eliminate diseases but, behind the pretext of this noble cause, it is demanding blind obedience from hundreds of millions of patients. As with the breath-monitoring device developed by researchers at the University of Florida and Xhale, therefore, some might argue that one of the long-term goals behind the approval of so-called “smart pills” could possibly be to force patients into taking patented chemical drug medicines by nullifying their medical and/or life insurance if it is discovered they have discontinued them.

U.S. to Force Drug Firms to Report Money Paid to Doctors

January 16, 2012

WASHINGTON – To head off medical conflicts of interest, the Obama administration is poised to require drug companies to disclose the payments they make to doctors for research, consulting, speaking, travel and entertainment.
Read article in the New York Times (USA)

Nurses' miscarriages linked to chemicals at work

January 13, 2012

Nurses who worked with chemotherapy drugs or sterilizing chemicals were twice as likely to have a miscarriage as their colleagues who didn't handle these materials, in a new study.
Read news report at reuters.com

Comment: Many people are simply not aware that the chemicals used in so-called chemotherapy are toxic and dangerous not just to the patients to whom they are administered, but also to the people they come in contact with. As these chemicals are excreted through the chemotherapy patient's skin, urine, stool, tears, semen and vaginal fluid, the people at risk of contamination include family members, caregivers and literally anyone touching him/her. To read shocking extracts from the "patient information leaflets" of these drugs, as published by the drug manufacturers themselves, click here.

Roche Faces First Trial of Claims Over Raptiva Infections

January 13, 2012

Roche Holding AG (ROG)'s Genentech Inc. is facing the first trial of patients' claims that its withdrawn Raptiva psoriasis drug spawned fatal infections in some users.
Read article at Bloomberg.com

UK survey finds science misconduct “alive and well”

January 12, 2012

More than one in 10 British-based scientists or doctors have witnessed colleagues intentionally altering or fabricating data during their research, according to a survey by the British Medical Journal (BMJ) on Thursday.
Read article in the Baltimore Sun (Maryland/US)

A Texas Official On The Johnson & Johnson Payroll

January 12, 2012

Earlier this week, a widely anticipated trial began in an Austin, Texas courtroom, where Johnson & Johnson is accused of orchestrating a controversial program that was allegedly designed to boost the use of the Risperdal antipsychotic in the public sector. A whistleblower lawsuit filed in 2004 described how J&J surreptitiously created and funded TMAP, or the Texas Medication Algorithm Project.
Read article and watch video at pharmalot.com

Move by former agency boss 'damaging' public trust in EU

January 11, 2012

New evidence alleges that the former head of the European Medicines Agency (EMA) set up his own consultancy business to advise pharmaceutical industry clients while he was still employed as the head of EMA. It is said this is “damaging the trust that European citizens should place in officials appointed to protect public health”.
Read article at theparliament.com

Comment: Revealing though this news is, it could be argued that public trust in the 'Brussels EU' could hardly be damaged any further than it already is. Anyone aware of the facts regarding the ongoing attempts by the 'Brussels EU' to curtail the spread of lifesaving natural health information will long ago have lost complete trust in the officials supposedly appointed by it to “protect public health.” As a result, awareness is growing worldwide that dismantling the 'Brussels EU' is now a precondition for global natural health freedom.

Statins Could Aggravate Diabetes Risk in Women: Study

January 11, 2012

Diabetes could be an added risk for women taking the cholesterol-lowering drug, more popularly touted as statins. The research, published in the Jan. 9 issue of the Archives of Internal Medicine, states that postmenopausal women on statins have a higher risk of developing diabetes.
Read on the website of the International Business Times

Pradaxa Side Effect Reports Were Hemorrhaging

January 11, 2012

Just when you thought the clouds hovering the Pradaxa bloodthinner could not get any darker, yet another report underscores concern about the Boehringer Ingelheim drug. The latest missive shows there were 505 cases of hemorrhaging reported to the FDA in the first quarter of 2011, shortly after the med was approved for preventing stroke and blood clots in people with atrial fibrillation. The cases resulted in death, disability, hospitalization or some other serious outcome, and the median age of the patients was 80, suggesting that the oldest and most vulnerable patients were hemorrhaging due to a drug overdose, according to the Quarter Watch reported from the Institute for Safe Medicine Practices, a non-profit.
Read article at pharmalot.com

GlaxoSmithKline fined over trials on the babies of Argentinian poor

January 11, 2012

GlaxoSmithKline, Britain's biggest drug firm, has been fined by an Argentine court over clinical trials of a pneumonia vaccine which was tested on thousands of babies from poor families. The firm failed to get proper consent from the children's parents before injecting Synflorix, one of its bestselling vaccines, according to a judge in Buenos Aires. GSK was also criticised for keeping inadequate records of the children's ages, medical histories and previous jabs.
Read article in the Daily Telegraph (UK)

Deadly peril in an aspirin

January 10, 2012

Healthy people who take aspirin to prevent heart attacks and strokes are putting themselves in greater danger of life-threatening internal bleeding. They are increasing the risks by as much as a third, scientists are warning.
Read article in the Daily Express (UK)

Comment: Additional research suggests that regular use of aspirin also increases the risk of developing Crohn's disease; irregular heart rhythm; erectile dysfunction; hearing loss; and blindness.

Pfizer Must Pay $45 Million in Prempro Cases, Court Rules

January 6, 2012

Pfizer Inc. must pay more than $45 million in damages to two women who blamed the company's menopause drugs for their breast cancers, an appeals court ruled.
Read article at businessweek.com

Parents sue Pfizer over birth defects allegedly caused by Zoloft

January 5, 2012

A group of parents who claim their children suffered severe birth defects because of Zoloft has filed a lawsuit against the drug's manufacturer.
Read article in the Madison/St. Clair Record (USA)